Oncothyreon (ONTY) Commences ONT-380 Combo Phase 2 Dosing in HER2-Positive Breast Cancer
Tweet Send to a Friend
Oncothyreon Inc. (Nasdaq: ONTY) announced dosing of the first patient in a randomized, placebo-controlled Phase 2 trial of ONT-380 in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
